Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
News

Hormone therapy study restokes debate over breast cancer risk

Lauren Vogel
CMAJ September 30, 2019 191 (39) E1088-E1089; DOI: https://doi.org/10.1503/cmaj.1095815
Lauren Vogel
CMAJ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

A meta-analysis has linked menopausal hormone therapy to increased risk of breast cancer, but some experts argue that the study is flawed.

The paper, published in the Lancet, showed there was one additional case of breast cancer for every 50 average-weight women aged 50–69 in developed countries who took daily doses of estrogen and progesterone for five years. The risk increased the longer women took the therapy and persisted more than a decade after they stopped, twice as long as previously thought.

The findings have revived a longstanding debate over the safety of hormone replacement therapy (HRT), with some critics of the meta-analysis warning that it overstates the risks. The authors, however, say there are no easy answers and women must weigh the risks and benefits for themselves.

“We don’t want to cause undue alarm and we don’t want to cause undue reassurance,” said coauthor Sir Richard Peto, a professor of medical statistics and epidemiology at the University of Oxford in England. “It’s the job of doctors to help patients to get a feel for what’s right for them.”

Peto and coauthors conducted a meta-analysis of 58 studies, which included 143 887 postmenopausal women with invasive breast cancer and 424 972 who did not develop breast cancer. The risk of breast cancer was found to have increased the longer women used hormone therapy, doubling for women who used it for 10 years compared to five. However, there was no increased risk for women who used hormone therapy for less than a year, and those who used it intermittently were found to have lower risk than those who used it daily.

These findings support existing recommendations that women use hormone therapy for the shortest time and at the lowest dose that works for them, said Dr. Robert Langer, board member of the International Menopause Society. However, he and others warn, the meta-analysis isn’t applicable to modern HRT regimens and overstates the risks, especially for younger women.

According to the International Menopause Society and the British Menopause Society, most of the data in the Lancet paper are from older observational studies of formulations and doses of hormone therapy that are no longer recommended.

Peto said using older data can’t be avoided in a study of long-term effects. He’s also skeptical that newer forms of HRT would be much different. “You have to give enough dose to have a pharmacological effect, and it’s not clear that the effective suppression of symptoms can be disassociated from unwanted effects on breast cells.”

Figure

A meta-analysis that shows breast cancer risk increases the longer women take hormone replacement therapy has revived longstanding debate over the safety of the treatment.

Image courtesy of iStock.com/Chinnapong

The International Menopause Society also cautions that breast cancer risk reported for women who go through menopause before age 45 must be seen in context of the risk they would face if they still had their periods. Women who go through early menopause have a third lower risk of breast cancer to begin with, said Langer. Hormone replacement therapy restores their risk to what it would have been if they still had their periods, but also provides protective benefits against osteoporosis, cardiovascular disease and premature death. “They should not be scared away by a paper like this.”

Langer acknowledged that the decision is more complicated for older women. But for those suffering from hot flashes that keep them up all night, or other disruptive symptoms of menopause, the relief HRT provides may be worth the added risk.

According to Peto, there are other ways to reduce the risk of cardiovascular disease and osteoporosis that don’t carry added risk for breast cancer. He also questions the independence of organizations like International Menopause Society from pharmaceutical funding. “I think that they are selective in what they present as evidence.”

Footnotes

  • Posted on cmajnews.com on Sept. 10, 2019

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 191 (39)
CMAJ
Vol. 191, Issue 39
30 Sep 2019
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Hormone therapy study restokes debate over breast cancer risk
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Hormone therapy study restokes debate over breast cancer risk
Lauren Vogel
CMAJ Sep 2019, 191 (39) E1088-E1089; DOI: 10.1503/cmaj.1095815

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Hormone therapy study restokes debate over breast cancer risk
Lauren Vogel
CMAJ Sep 2019, 191 (39) E1088-E1089; DOI: 10.1503/cmaj.1095815
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Footnotes
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Saying goodbye to CMAJ News
  • How Canadian hospitals are decreasing carbon emissions
  • National survey highlights worsening primary care access
Show more News

Similar Articles

Collections

  • Topics
    • Drugs: hormones & metabolic agents
    • Obstetrics & gynecology
    • Women's health (including abortion)

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

CMA Civility, Accessibility, Privacy

 

Powered by HighWire